To this end, Zhang and colleagues,1 focusing on redox status of the DTP cancers from MDR cancer cells, identified a novel vulnerability—NPC1L1, a specific target of an antihyperlipidemic drug that has been approved by the United States Food and Drug Administration, ezetimibe. This evidence concerns the gene NPC1L1 and cancer.